SGMO
Sangamo Therapeutics Inc.
$0.55
+$0.01(+0.93%)
50
Overall
--
Value
50
Tech
--
Quality
Market Cap
$155.14M
Volume
3.56M
52W Range
$0.41 - $3.18
Target Price
$4.10
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $39.5M | $19.4M | $36.6M | $84.5M | $102.4M | $118.2M | $110.7M | $111.3M | $176.2M | $57.8M | ||
| Total Revenue | $39.5M | $19.4M | $36.6M | $84.5M | $102.4M | $118.2M | $110.7M | $111.3M | $176.2M | $57.8M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $39.5M | $19.4M | $36.6M | $84.5M | $102.4M | $118.2M | $110.7M | $111.3M | $176.2M | $57.8M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-86.4M | $-91.9M | $-92.9M | $-161.6M | $207.6M | $247.7M | $294.0M | $312.6M | $450.2M | $161.8M | ||
| Research & Development | $67.2M | $65.6M | $65.7M | $114.9M | $145.9M | $180.6M | $230.8M | $249.9M | $234.1M | $111.5M | ||
| Research Expense | $67.2M | $65.6M | $65.7M | $114.9M | $145.9M | $180.6M | $230.8M | $249.9M | $234.1M | $111.5M | ||
| Selling, General & Administrative | $19.2M | $26.3M | $27.2M | $46.7M | $61.7M | $67.1M | $63.2M | $62.7M | $61.2M | $44.7M | ||
| General & Administrative Expenses | $19.2M | $26.3M | $27.2M | $46.7M | $61.7M | $67.1M | $63.2M | $62.7M | $61.2M | $44.7M | ||
| Salaries & Wages | $-11.7M | $-15.1M | $-9.1M | $-14.7M | -- | -- | -- | -- | $27.4M | -- | ||
| Depreciation & Amortization | $-988.0K | $-997.0K | $-1.5M | $-2.4M | $3.9M | $5.7M | $9.4M | $12.1M | $15.1M | $5.1M | ||
| Depreciation & Amortization | $-988.0K | $-997.0K | $-1.5M | $-2.4M | $3.9M | $5.7M | $9.4M | $12.1M | -- | $5.1M | ||
| Amortization | -- | -- | -- | -- | $53.2M | $58.1M | $53.8M | $50.7M | -- | -- | ||
| Other Operating Expenses | $-86.4M | $-91.9M | $-92.9M | $-161.6M | $-5.4M | $-2.8M | $-2.5M | $-3.2M | -- | $-4.3M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-46.9M | $-72.6M | $-56.4M | $-77.2M | $-105.2M | $-129.6M | $-183.3M | $-201.3M | $-274.0M | $-104.0M | ||
| EBITDA | $-44.6M | $-70.5M | $-53.7M | $-72.4M | $-90.5M | $-116.2M | $-165.7M | $-180.7M | $-240.7M | $-88.8M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Intinc | -- | $887.0K | $1.8M | $8.3M | $9.8M | $8.8M | $5.3M | $9.4M | $11.1M | $5.9M | ||
| Net Non-Operating Interest Income/Expense | -- | $887.0K | $1.8M | $8.3M | $9.8M | $8.8M | $5.3M | $9.4M | $11.1M | $5.9M | ||
| Other Income/Expense | $-431.0K | $-887.0K | -- | -- | -- | -- | -- | -- | $65.5M | $5.5M | ||
| Other Special Charges | $431.0K | $887.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $342.0K | ||
| Special Income Charges | -- | -- | -- | -- | -- | -- | -- | -- | $-89.5M | $-342.0K | ||
| Impairment of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | $89.5M | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-46.4M | $-71.7M | $-54.6M | $-68.9M | $-95.4M | $-129.6M | $-183.3M | $-201.3M | $-262.9M | $-98.1M | ||
| Pre-Tax Income | $-46.4M | $-71.7M | $-54.6M | $-68.9M | $-95.4M | $-120.8M | $-178.0M | $-191.8M | $-262.9M | $-98.1M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-5.7M | $-14.0K | $-53.0M | $-956.0K | $-9.6M | $345.0K | $306.0K | $429.0K | $-5.1M | $-167.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-40.7M | $-71.7M | $-54.6M | $-68.3M | $-95.2M | $-121.0M | $-178.3M | $-192.3M | $-257.8M | $-97.9M | ||
| Net Income (Continuing Operations) | $-40.7M | $-71.7M | $-54.6M | $-68.3M | $-95.2M | $-121.0M | $-178.3M | $-192.3M | $-257.8M | $-97.9M | ||
| Net Income (Discontinued Operations) | $-40.7M | $-71.7M | $-54.6M | $-68.3M | $-95.2M | $-121.0M | $-178.3M | $-192.3M | $-257.8M | $-97.9M | ||
| Net Income (Common Stockholders) | $-40.7M | $-71.7M | $-54.6M | $-68.3M | $-95.2M | $-121.0M | $-178.3M | $-192.3M | $-257.8M | $-97.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-93.4M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-86.4M | $-91.9M | $-92.9M | $-161.6M | $207.6M | $247.7M | $294.0M | $312.6M | $450.2M | $161.8M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $69.8M | $70.6M | $78.1M | $96.9M | $112.1M | $134.4M | $144.6M | $154.3M | $174.4M | $201.7M | ||
| Average Shares Outstanding (Diluted) | $70.2M | $70.3M | $78.0M | $97.6M | $112.1M | $134.4M | $144.6M | $154.3M | $174.4M | $201.7M | ||
| Shares Outstanding | $70.4M | $70.9M | $86.3M | $102.3M | $116.0M | $143.3M | $146.0M | $168.5M | $178.9M | $224.7M | ||
| Basic EPS | -- | -- | -- | -- | $-0.85 | $-0.90 | $-1.23 | $-1.25 | $-1.48 | $-0.49 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-0.85 | $-0.90 | $-1.23 | $-1.25 | $-1.48 | $-0.49 | ||
| Diluted EPS | $-0.58 | $-1.02 | $-0.70 | $-0.70 | $-0.85 | $-0.90 | $-1.23 | $-1.25 | $-1.48 | $-0.49 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $-1.23 | $-1.25 | $-1.48 | $-0.49 | ||
| OTHER METRICS | ||||||||||||
| Gain On Sale Of P P E | -- | -- | -- | -- | -- | -- | -- | -- | -- | $1.0M | ||
| Minority Interests | -- | -- | -- | $555.0K | $233.0K | $126.0K | $11.0K | -- | -- | -- | ||
| Other Gand A | $19.2M | $26.3M | $27.2M | $46.7M | $61.7M | $67.1M | $63.2M | $62.7M | $61.2M | $44.7M | ||
| Other Impairment Of Capital Assets | $-1.9M | -- | -- | -- | -- | -- | -- | -- | $65.5M | $5.5M | ||
| Rent And Landing Fees | $19.2M | $26.3M | $27.2M | $46.7M | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | -- | -- | -- | -- | -- | $342.0K | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SGMO | $0.55 | +0.9% | 3.56M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Sangamo Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW